Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.
However, H.C. Wainwright said they remain encouraged by the drug’s prospects, particularly in immune-mediated necrotizing myopathy (IMNM), which they believe could eventually generate more than $1 billion in sales.
Analyst Meeting Reveals Changes To Phase 3 Myositis Program
Citing a recent analyst meeting, analyst Douglas Tsao said Argenx’s Phase 3 readout for Vyvgart in myositis will now include separate analyses for the IMNM and dermatomyositis (DM) cohorts on the study’s primary endpoint.
Read Next
